Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2009;12(3):275-85.
doi: 10.1007/s10456-009-9150-8. Epub 2009 May 16.

Single and combined effects of alphavbeta3- and alpha5beta1-integrins on capillary tube formation in a human fibrinous matrix

Affiliations

Single and combined effects of alphavbeta3- and alpha5beta1-integrins on capillary tube formation in a human fibrinous matrix

Nancy Laurens et al. Angiogenesis. 2009.

Abstract

The fibrinous exudate of a wound or tumor stroma facilitates angiogenesis. We studied the involvement of RGD-binding integrins during tube formation in human plasma-derived fibrin clots and human purified fibrin matrices. Capillary-like tube formation by human microvascular endothelial cells in a 3D plasma-derived fibrinous matrix was induced by FGF-2 and TNF-alpha and depended largely on cell-bound u-PA and plasmin activities. While tube formation was minimally affected by the addition of either the alphavbeta3-integrin inhibiting mAb LM609 or the alpha5-integrin inhibiting mAb IIA1, the general RGD-antagonist echistatin completely inhibited this process. Remarkably, when alphavbeta3- and alpha5beta1-integrins were inhibited simultaneously, tube formation was reduced by 78%. It was accompanied by a 44% reduction of u-PA antigen accumulation and 41% less production of fibrin degradation products. alphavbeta5-integrin-blocking antibodies further enhanced the inhibition by mAb LM609 and mAb IIA1 to 94%, but had no effect by themselves. alphav-specific cRGD only inhibited angiogenesis when alpha5beta1-integrin was simultaneously blocked. Endostatin mimicked the effect of alpha5beta1-integrin and inhibited tube formation only in the presence of LM609 or cRGD (73 and 80%, respectively). Comparable results were obtained when purified fibrin matrices were used instead of the plasma-derived fibrinous matrices. These data show that blocking of tube formation in a fibrinous exudate requires the simultaneous inhibition of alphavbeta3- and alpha5beta1-integrins. This may bear impact on attempts to influence angiogenesis in a fibrinous environment.

PubMed Disclaimer

Figures

Fig. 1
Fig. 1
Localization of RGD-binding integrins in endothelial cells in vivo. Immunohistochemistry was performed on paraffin sections of a recanalized mural thrombus formed in a human coronary artery as described in Materials and Methods. a Phloxin staining; b Immunostaining of endothelial cells by CD31; c Immunostaining of αvβ3-integrin by mAb LM609; d Immunostaining of αvβ5-integrin by rabbit anti-human β5-integrin antibody; e Immunostaining of α5β1-integrin by rabbit anti-human α5-integrin antibody
Fig. 2
Fig. 2
Blocking of αvβ3- and α5β1-integrins results in a combined effect on the inhibition of capillary-like tube formation in plasma-derived fibrinous matrices. HMVECs cultured on a three-dimensional fibrinous plasma clot were not stimulated (control) or stimulated with FGF-2/TNF-α in the absence or presence of the αvβ3-blocking mAb LM609 (10 μg/ml), the αvβ5-blocking mAb P1F6 (10 μg/ml), the α5-blocking mAb IIA1 (2 μg/ml) or the combinations of these mAbs. After 6 days of culturing, the mean tube length of duplicate wells was quantified (mm/cm2) as described (a). The data represent mean % ± SEM of FGF-2/TNF-α stimulated tube formation of 3–7 independent experiments. The mean tube length of FGF-2/TNF-α in the plasma-derived fibrinous matrix was 70 ± 20 mm/cm2. b After 6 days of culturing, non-phase photomicrographs were taken of hMVECs stimulated with FGF-2/TNF-α in the absence or presence of LM609, IIA1 or the combination of these mAbs in the concentrations described above. Bar represents 300 μm. * P < 0.01 as compared to 100% (=FGF-2/TNF-α stimulated condition)
Fig. 3
Fig. 3
Combined effect of endostatin, LM609, and/or cRGD on capillary-like tube formation in fibrinous plasma clots. HMVECs cultured on a three-dimensional plasma clot were not stimulated (control) or stimulated with FGF-2/TNF-α in the presence of either endostatin (10 μg/ml), the αvβ3-blocking mAb LM609 (10 μg/ml), the α5-blocking mAb IIA1 (2 μg/ml) or cRGD (50 μg/ml), a combination of endostatin and LM609, endostatin and IIA1, cRGD and endostatin, or IIA1 and cRGD. After 6 days of culturing, the mean tube length was quantified (mm/cm2) as described. The data represent mean % ± SEM of FGF-2/TNF-α stimulated tube formation of 3–5 independent experiments. The mean tube length of FGF-2/TNF-α was 98 ± 15 mm/cm2. * P < 0.05, ** P < 0.01 as compared to 100% (=FGF-2/TNF-α stimulated condition)
Fig. 4
Fig. 4
Blocking of αvβ3- and α5β1-integrins results in a combined effect on the inhibition of capillary-like tube formation in purified fibrin matrices. HMVECs cultured on a three-dimensional fibrin matrix and were not stimulated (control) or stimulated with FGF-2/TNF-α in the absence or presence of the αvβ3-blocking mAb LM609 (10 μg/ml), the αvβ5-blocking mAb P1F6 (10 μg/ml), the α5-blocking mAb IIA1 (2 μg/ml) or the combinations of these mAbs. After 6 days of culturing, the mean tube length of duplicate wells was quantified (mm/cm2) as described (a). The data represent mean % ± SEM of FGF-2/TNF-α stimulated tube formation of 3–7 independent experiments. The mean tube length of FGF-2/TNF-α in the purified fibrin matrix was 83 ± 4 mm/cm2. b After 6 days of culturing, non-phase photomicrographs were taken of hMVECs stimulated with FGF-2/TNF-α in the absence or presence of LM609, IIA1 or the combination of these mAbs in the concentrations described above. Bar represents 300 μm. *P < 0.01 as compared to 100% (=FGF-2/TNF-α stimulated condition)
Fig. 5
Fig. 5
Analysis of the human and mouse fibrinogen. Scanning electron microscopy of human (a) and mouse (b) plasma-derived fibrin clots. Bar represents 1 μm. c Schematic representation of the fibrinogen Aα-chain in human and mouse plasma

Similar articles

Cited by

References

    1. {'text': '', 'ref_index': 1, 'ids': [{'type': 'DOI', 'value': '10.1038/nm0603-653', 'is_inner': False, 'url': 'https://doi.org/10.1038/nm0603-653'}, {'type': 'PubMed', 'value': '12778163', 'is_inner': True, 'url': 'https://pubmed.ncbi.nlm.nih.gov/12778163/'}]}
    2. Carmeliet P (2003) Angiogenesis in health and disease. Nat Med 9:653–660. doi:10.1038/nm0603-653 - PubMed
    1. {'text': '', 'ref_index': 1, 'ids': [{'type': 'DOI', 'value': '10.1038/nm0195-27', 'is_inner': False, 'url': 'https://doi.org/10.1038/nm0195-27'}, {'type': 'PubMed', 'value': '7584949', 'is_inner': True, 'url': 'https://pubmed.ncbi.nlm.nih.gov/7584949/'}]}
    2. Folkman J (1995) Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat Med 1:27–31. doi:10.1038/nm0195-27 - PubMed
    1. {'text': '', 'ref_index': 1, 'ids': [{'type': 'PubMed', 'value': '3537791', 'is_inner': True, 'url': 'https://pubmed.ncbi.nlm.nih.gov/3537791/'}]}
    2. Dvorak HF (1986) Tumors: wounds that do not heal similarities between tumor stroma generation and wound healing. N Engl J Med 315:1650–1659 - PubMed
    1. {'text': '', 'ref_index': 1, 'ids': [{'type': 'PubMed', 'value': '11460496', 'is_inner': True, 'url': 'https://pubmed.ncbi.nlm.nih.gov/11460496/'}]}
    2. van Hinsbergh VWM, Collen A, Koolwijk P (2001) Role of fibrin matrix in angiogenesis. Ann N Y Acad Sci 936:426–437 - PubMed
    1. {'text': '', 'ref_index': 1, 'ids': [{'type': 'DOI', 'value': '10.1200/JCO.2002.10.088', 'is_inner': False, 'url': 'https://doi.org/10.1200/jco.2002.10.088'}, {'type': 'PubMed', 'value': '12409337', 'is_inner': True, 'url': 'https://pubmed.ncbi.nlm.nih.gov/12409337/'}]}
    2. Dvorak HF (2002) Vascular permeability factor/vascular endothelial growth factor: a critical cytokine in tumor angiogenesis and a potential target for diagnosis and therapy. J Clin Oncol 20:4368–4380. doi:10.1200/JCO.2002.10.088 - PubMed

Publication types

MeSH terms